Xenon Pharmaceuticals Inc. — Director's Dealing 2018

Jun 22, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2018-06-21

Reporting Person: TARNOW MICHAEL M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-21	Common Shares	M	5144	$3.70	Acquired	60311	Direct
2018-06-21	Common Shares	M	2057	$3.66	Acquired	62368	Direct
2018-06-21	Common Shares	M	5144	$3.07	Acquired	67512	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-21	Stock Option (Right to Buy)	$3.70	M	5144	Disposed	2018-06-26	Common Shares (5144)	Direct
2018-06-21	Stock Option (Right to Buy)	$3.66	M	2057	Disposed	2018-06-30	Common Shares (2057)	Direct
2018-06-21	Stock Option (Right to Buy)	$3.07	M	5144	Disposed	2018-12-31	Common Shares (5144)	Direct

Footnotes

F1: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F2: The shares subject to the option fully vested on May 31, 2011.

F3: The shares subject to the option fully vested on June 30, 2011.

F4: The shares subject to the option fully vested on December 31, 2011.